

The logo features the text 'LHON' in a large, bold, white sans-serif font, with 'A W A R E' in a smaller, spaced-out white sans-serif font below it. A teal-colored wedge is positioned behind the 'O' in 'LHON' and extends upwards and to the right. The background consists of several overlapping circles in various shades of green.

**LHON**  
A W A R E

**Leber's Hereditary  
Optic Neuropathy**

## LHON causes rapid, painless, central loss of vision, typically leading to blindness<sup>1,2</sup>

### WARNING SIGNS for SUSPICION of LHON<sup>1-4,10,11</sup>

- **Rapid, painless, central loss of vision**
- One eye affected initially, followed by the second eye within weeks to months
- Family history of loss of vision or LHON\*
- Most often central or centrocaecal scotoma
- The pupillary light reflex is relatively preserved despite the severity of optic atrophy<sup>6</sup>
- Peripapillary telangiectatic microangiopathy and hyperemia of the optic disc in the acute stage
- Optic disc pseudo-oedema and RNFL<sup>#</sup> thickening in the first months after disease onset, followed by progressive thinning<sup>7\*\*</sup>
- Early and persistent ganglion cell inner plexiform layer thinning detectable before onset of visual loss<sup>8</sup>
- Lack of response to glucocorticoid treatment
- In chronic phase, cupping of the optic disc can be observed in addition to pallor of the neuroretinal rim and RNFL thinning<sup>12</sup>

**LHON** typically presents in males aged 15-35, but can occur in either sex at any age.

\*Family history of LHON may be absent in up to 40% of cases<sup>5</sup>

\*\*Retina can lack typical features of LHON in 20-40% of cases<sup>9</sup> #RNFL - retinal nerve fiber layer

1. Yu-Wai-Man P, et al. Prog Retin Eye Res. 2011; 30: 81-114. 2. Mascialino B, et al. Eur J Ophthalmol. 2012; 22: 461-465. 3. Newman NJ, Nat Rev Neurol. 2012; 8: 545-556. 4. Fraser JA, Biousse V, Newman NJ. Surv Ophthalmol. 2010; 55: 299-334. 5. Yu-Wai-Man P, et al. J Med Genet. 2002 39(3):162-9. 6. Moura AM, et al. Invest Ophthalmol Vis Sci. 2013; 54(7): 4471-4477. 7. Barboni P, et al. Ophthalmology. 2010; 117(3): 623-7. 8. Balducci N, et al. y, Br J Ophthalmol. 2016; 100: 1232-1237. 9. Yu-Wai-Man P, et al. Eye. 2014; 28(5): 521-37. 10. Carelli V, et al. J Neuroophthalmol. 2017 Dec; 37(4):371-381. 11. Sundaramurthy S, et al. Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2461-2472. 12. Mashima Y, et al. Graefes Arch Clin Exp Ophthalmol. 2003, 241(2):75-80.

#### Chiesi Pharma AB

Klara Norra kyrkogata 34, 111 22 Stockholm, Telefon +46 8 753 35 20  
www.chiesipharma.se | www.chiesipharma.dk | www.chiesi.no | www.chiesi.fi | infonordic@chiesi.com